Go Pro

Hemab Therapeutics (COAG) Earnings Date, Estimates & Call Transcripts

Hemab Therapeutics logo
$44.84 -4.65 (-9.40%)
As of 08/28/2026 04:00 PM Eastern

Hemab Therapeutics Earnings Summary

Hemab Therapeutics posted Q2 2026 earnings on August 11, 2026, reporting an EPS of -$0.80, which missed the consensus estimate of -$0.63 by $0.17. With a trailing EPS of -$24.78, Hemab Therapeutics' earnings are expected to grow next year, from ($3.09) to ($2.64) per share.

Consensus EPS
(Aug. 11)
-$0.63
Actual EPS
(Aug. 11)
-$0.80 Missed By -$0.17

Q2 2026 Earnings Resources

Get Hemab Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemab Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

COAG Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Hemab Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20261-$0.69-$0.69-$0.69
Q3 20261-$0.54-$0.54-$0.54
Q4 20261-$0.57-$0.57-$0.57

Hemab Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026-$0.63-$0.80 -$0.17-$0.80--
5/21/2026Q1 2026--$23.98--$23.98--

Hemab Therapeutics Earnings - Frequently Asked Questions

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earning data on Tuesday, August 11, 2026. Learn more on COAG's earnings history.

In the previous quarter, Hemab Therapeutics (NASDAQ:COAG) missed the analysts' consensus estimate of ($0.63) by $0.17 with a reported earnings per share (EPS) of ($0.80). Learn more on analysts' earnings estimate vs. COAG's actual earnings.

Hemab Therapeutics' earnings are expected to grow from ($3.09) per share to ($2.64) per share in the next year.


Earnings data for NASDAQ:COAG is sourced from Fiscal.ai, with the most recent quarter reported on 8/11/2026. New results are added as companies report their earnings.
From Our Partners